Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 4/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251322 | 1.00 | CPB1 (0.47) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL15251346 | 0.91 | CPB1 (0.49) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL2826203 | 0.91 | CPB1 (0.49) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL2823788 | 0.86 | CPB1 (0.54) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL30400185 | 0.86 | CPB1 (0.54) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL30401008 | 0.86 | CPB1 (0.54) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL5227905 | 0.86 | CPB1 (0.54) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL13329888 | 0.86 | ALDH1A1 (0.46) | CPB1ALDH1A1GAATACR1NAAA | |
| SCHEMBL13330261 | 0.86 | ALDH1A1 (0.46) | CPB1ALDH1A1GAATACR1NAAA | |
| Hydrochloric Acid SCHEMBL2823828 | 0.85 | CPB1 (0.53) | CPB1ALDH1A1GAATACR1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| WO-2015101293-A1 | KINASE INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | CPB1 4053/4885ALDH1A1 2078/4885GAA 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.